Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 6;20(8):30.
doi: 10.1007/s11882-020-00928-2.

Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine

Affiliations
Review

Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine

Ian F Slack et al. Curr Allergy Asthma Rep. .

Abstract

Purpose of review: Recent research efforts have spurred great progress in the diagnosis and management of eosinophilic esophagitis (EoE). Nonetheless, challenges remain in addressing disease burden and impairment in the growing EoE population. We highlight work from the Cincinnati Center for Eosinophilic Disorders, the Consortium of Eosinophilic Gastrointestinal Disease Researchers, and others that address these ongoing challenges.

Recent findings: New tools for characterizing EoE disease activity include the EoE Histology Scoring System (EoEHSS), endoscopic alternatives, validated patient-reported outcome (PRO) questionnaires, and investigational biomarkers. These diagnostic and monitoring strategies have been complemented by advances in EoE therapy. Treatment modalities have refined the traditional approaches of dietary elimination, swallowed steroids, and proton pump inhibitors (PPI), and biologics offer promise for future treatment. This review summarizes EoE advances in disease management and newly defined EoE endotypes that may serve as the foundation for EoE-personalized medicine.

Keywords: Diagnosis; Endotype; Eosinophilic esophagitis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Mrs. Hottinger reports grants from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR; Administrative Core, U54AI117804), outside the submitted work. Dr. Mukkada reports consulting fees from Shire/Takeda, outside the submitted work. The other authors declare no conflicts of interest relevant to this manuscript.

Figures

Fig. 1
Fig. 1
Evolution of EoE diagnosis and management over the past 25 years. EoE, eosinophilic esophagitis; anti-interleukin pathway antibodies; PPI-REE, proton pump inhibitor-responsive esophageal eosinophilia

References

    1. Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109(5):1503–12. - PubMed
    1. Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated International Consensus Diagnostic Criteria for eosinophilic esophagitis: proceedings of the AGREE Conference. Gastroenterology. 2018;155(4):1022–33 e10 - PMC - PubMed
    2. Most recent EoE consensus guidelines, incorporating PPI-REE into EoE diagnosis.

    1. Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108(6): 954–61. - PubMed
    1. Pentiuk S, Putnam PE, Collins MH, Rothenberg ME. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009;48(2):152–60. - PMC - PubMed
    1. DeBrosse CW, Collins MH, Buckmeier B, Greenburg A, Allen C, Abonia JP, et al., editors. The “epidemic” of eosinophilic esophagitis (ee) is due to increased recognition of a chronic disorder. J Allergy Clin Immunol; 2010.

Publication types

MeSH terms